| 释义 |
Ultralente, n. Med. and Pharm.|ʌltrəˈlɛntɪ|
Also with hyphen, as two words, and with capital initial.
[a. Da. Ultralente (registered in Denmark in 1952), f. L. ultrā (see ultra-) + lentē slowly (see *lente n.)]
(A proprietary name in the U.S. for) a form of insulin that is absorbed into the body more slowly after its introduction than lente insulin; also applied loosely to any such slow-release insulin. Usu. as adj., designating insulin of this type.
1953Brit. Med. Jrnl. 31 Jan. 243/1 The action of amorphous insulin is shorter than that of crystalline, the larger the size of the crystal the greater being the length of activity. Three such insulins have been produced and given the names of ‘semi-lente’, ‘lente’, and ‘ultra-lente’, the first having the shortest and the last the longest range of activity. 1959Official Gaz. (U.S. Patent Office) 21 July tm99/1 Ultralente... For preparation for the treatment of diabetes. 1964Indian Jrnl. Physiol. & Pharmacol. VIII. 127 Administration of Ultra Lente Insulin to male rats caused an increase of blood pressure and an enhanced response to the pressor action of angiotensin in a significant number of animals. 1977Lancet 15 Oct. 801/1 He rightly dismisses protamine zinc and ultralente insulins as having no place in the modern treatment of diabetes. 1984Diabetes Care VII. 331 Twelve diabetic subjects were treated 3 mo with CSII and 3 mo with MI (bedtime ultralente and premeal boluses of regular insulin). 1986J. K. Davidson Clin. Diabetes Mellitus xvi. 218/2 Lente insulin is a mixture of three parts of semilente insulin and seven parts of ultralente insulin. |